Tradestie Institutional Equity Comparison Engine
OBIO vs ICCC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (2โ2 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus ICCC at N/M Forward P/E and 15.2% operating margin (+11.5% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
ICCC
OBIO N/M vs ICCC N/M Fwd P/E
Growth & Margin Winner
ICCC
Op Margin -195.4% vs 15.2% ยท YoY -89.4% vs +11.5%
Momentum & Technical Winner
OBIO
1Y +70.3% vs +88.8% ยท 52W Pos 92% vs 91%
Options & Structure Winner
OBIO
BREAKOUT (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
OBIO
NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap
$570.6M
1M Return
+30.64%
1Y Return
+70.33%
Forward P/E
N/M
Unified AI Score
37.5 / 100
SELL
Tech 15.0
Fund 36.0
Flow 55.0
Mom 44.0
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
OBIO +70.33%
ICCC +88.76%
Spread: +18.43 pp (ICCC Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | ICCC Revenue | OBIO Op. Margin | ICCC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -13.2% | ICCC |
| FY2019 | N/A | $10M | N/A | -7.0% | ICCC |
| FY2020 | N/A | $20M | N/A | -9.0% | ICCC |
| FY2021 | N/A | $20M | N/A | 1.3% | ICCC |
| FY2022 | $0M | $20M | -924.3% | -12.4% | ICCC |
| FY2023 | $0M | $20M | -1866.2% | -32.9% | ICCC |
| FY2024 | $0M | $30M | -2437.5% | -6.2% | ICCC |
| FY2025 | $30M | $30M | -154.7% | 6.0% | ICCC |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OBIO | ICCC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $570.6M | $97.7M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | 56.6x | Lower Multiple | ICCC |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -89.4% | +11.5% | Higher Growth | ICCC |
| Operating Margin (TTM) Profitability | -195.4% | 15.2% | Higher Margin | ICCC |
| Net Profit Margin Profitability | -182.5% | 2.6% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | -182.3% | 2.6% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 92% ($3โ$7) | 91% ($5โ$12) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 1.15ฮฒ ยท 82% Vol | 0.24ฮฒ ยท 46% Vol | Lower Realized Risk | ICCC |
| Unified Institutional Score Composite Signal | 37.5 / 100 (SELL) | 43.8 / 100 (HOLD) | Higher Composite | ICCC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full OBIO vs ICCC Buy Guide
OBIO
BREAKOUT
32d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither OBIO nor ICCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.